If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

11 Mar 2009 07:00

RNS Number : 6511O
Sopheon PLC
11 March 2009
Ā 



Embargoed Release:Ā 07:00hrs Wednesday 11 March 2009

Sopheon plc

('Sopheon')

Ciba Implements Sopheon's Accolade® Solution to Help Focus Innovation Investments on Most Promising Projects

PLM SoftwareĀ SupportsĀ Global InitiativeĀ Aimed atĀ Improving Innovation GovernanceĀ andĀ Increasing Profits and Revenues from New Products

MINNEAPOLISĀ andĀ LONDONĀ -Ā Mar.Ā 11,Ā 2009Ā -Ā Sopheon,Ā theĀ internationalĀ provider of software and services for product lifecycle managementĀ (PLM), announced today thatĀ CibaĀ Inc.Ā ('Ciba'),Ā aĀ leadingĀ globalĀ manufacturerĀ ofĀ specialty chemicals,Ā isĀ implementingĀ Sopheon'sĀ Accolade product portfolio and innovation process managementĀ solution. Ciba's deployment of the Sopheon system is core to a global initiative aimed at improving returns on innovation investments. The software is being usedĀ toĀ enhanceĀ the company'sĀ capacity toĀ govern its innovation processes and focus resources on high-value product innovation projects.Ā Ā AccoladeĀ hasĀ been made available to more than 900Ā individualsĀ on cross-functional teamsĀ responsible forĀ product developmentĀ atĀ CibaĀ locations throughout Europe, Asia and theĀ United States.Ā 

Ciba's pedigree as an industry innovatorĀ began to developĀ more thanĀ two-and-a-half centuriesĀ agoĀ when, in 1758,Ā the companyĀ was foundedĀ as a trader in chemicals and dyes. In the ensuing years,Ā CibaĀ has been responsible for scientific breakthroughs in areas ranging fromĀ high-performance pigments and antimicrobials,Ā to chemical agents that keep vehicle coatings from peeling after excessive exposure to sunlight. Today the company focuses on the development and production of specialty chemicals, serving customers in more than 120 countries.

In 2006Ā CibaĀ set in motion an enterprise-wideĀ effortĀ called Operational Agenda. Its purposeĀ is to strengthen the company's growth and profitability. TheĀ programĀ is supported byĀ six strategic pillars, including an initiative dedicated to promoting innovation.Ā Ā A principal goal of thatĀ initiativeĀ isĀ toĀ reduce the overall number of projects in the new-product pipeline and ensure thatĀ R&DĀ resourcesĀ areĀ focused onĀ thoseĀ opportunitiesĀ that promise high business returns.Ā Ā It includes Ciba's implementation of aĀ comprehensive newĀ framework forĀ managingĀ itsĀ innovation efforts.

Ā  Ā 

Sopheon'sĀ AccoladeĀ solutionĀ will serve asĀ the key software component forĀ Ciba'sĀ management of its innovationĀ system. TheĀ selectionĀ of AccoladeĀ was based on a mix of advantages, including the fact that it could be readily configured to Ciba's specific requirements and, once in place, was easy to use. The software's governing capabilities are expected to improve product-development efficiency andĀ qualityĀ ofĀ execution,Ā by prompting users toĀ follow prescribedĀ processĀ stepsĀ andĀ address the right business and technical questions at the right timesĀ to optimise the chances of successĀ for projects in the pipeline. Project management will be enhanced by increased transparencyĀ asĀ AccoladeĀ system managersĀ are able to not onlyĀ retrieve instant updates onĀ theĀ statusĀ of individual projects,Ā butĀ toĀ accessĀ consolidated views that allow them toĀ assessĀ the cost, value and priorityĀ ofĀ projects comprising entire portfolios.

"The introduction of Sopheon's Accolade system accompanied the rejuvenation of Ciba's innovation infrastructure," saidĀ Martin Riediker, chiefĀ innovationĀ officer for Ciba. "TheĀ solutionĀ hasĀ providedĀ usĀ with aĀ state-of-the-artĀ innovation management system. For the first time, we areĀ ableĀ toĀ monitor all aspects of our R&DĀ initiativesĀ and makeĀ truly well-informed decisionsĀ about which ones to support. As a result, we are in a position toĀ significantly reduce the number of active projects in our development pipeline, andĀ toĀ back theĀ most promisingĀ opportunities with more resources. Ultimately,Ā AccoladeĀ will also allow us toĀ trackĀ andĀ assessĀ the returns on ourĀ innovationĀ investments.Ā Ā It givesĀ us the foundation we need to achieve profitable growth from product innovation well into the future."

Sopheon partners, Sopheon Vertriebs GmbH and Sopheon Business Applications GmbH, were responsible for the sale, implementation and support of Accolade atĀ Ciba.

Dieter Jaeger, chief executive officer of Sopheon Vertriebs GmbH, said, "Innovation has played a critical role throughout Ciba's history. The company'sĀ current strategic initiative on innovation is a comprehensive, multi-faceted approach to innovation management. Sopheon's softwareĀ has been characterised by Ciba as 'the glue that holds it allĀ together.'Ā Ā WithĀ the introductionĀ of Accolade,Ā CibaĀ isĀ movingĀ theĀ oversight and management of its innovation efforts to aĀ wholeĀ new level."Ā 

Accolade is a registered trademark of Sopheon plc

-Ends-

For further information:

Barry Mence, Chairman

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Vikki Krause

Hansard Communications

+ 44 (0) 207 245 1100

+ 44 (0) 7957 203 685

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

Paul Davies,Ā 

Corporate Finance

SeymourĀ Pierce

+ 44 (0) 207 107 8000

About Ciba Inc.

Ciba (SWX: CIBN) is a leading global company dedicated to producing high-value effects for its customers' products.Ā Ā Its productsĀ add performance, protection, colour and strength to plastics, paper, automobiles, buildings, home and personal care products and much more. Ciba is active in more than 120 countries around the world and is committed to being a leader in its chosen markets. In 2008, theĀ company generated sales of CHFĀ 5.9Ā billion from continued operations and invested over CHF 230Ā millionĀ in R&D. For more information, please visitĀ www.ciba.com.

About Sopheon

Sopheon (LSE:SPE) is an international provider of product lifecycle management software and services. Its solutions help organizations increase revenues and profits from new products by synchronizingĀ innovationĀ planning and execution. Sopheon's Accolade® software automates the product innovation process and provides strategic decision support for the management of product portfolios. Its Vision Strategist™ solution automates the roadmapping process, allowing users to visualize and forecast the future of products, markets and technologies. Sopheon's solutions are used by industry leaders throughout the world, including BASF, Cadbury Schweppes,Ā Corning, Electrolux, General Motors, Honeywell, Motorola, Nestle and SAB Miller. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in theĀ Netherlands. For more information, please visitĀ www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
NRASFIFASSUSESD
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.